search
Back to results

Treatment of Fecal Incontinence After Obstetric Anal Sphincter Injuries (KISS)

Primary Purpose

Fecal Incontinence

Status
Completed
Phase
Not Applicable
Locations
Norway
Study Type
Interventional
Intervention
Medtronic Interstim II-3058
Anal bulking injection
Sponsored by
University Hospital of North Norway
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Fecal Incontinence focused on measuring fecal incontinence, anal incontinence, obstetric sphincter injuries, OASIS, double incontinence, urinary incontinence, sexual function, sacral nerve modulation, sacral nerve stimulation, Interstim, anal bulking injections, Permacol

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)FemaleDoes not accept healthy volunteers

Inclusion Criteria:

  • fecal incontinence after OASIS
  • St Marks score > 8
  • failure of conservative treatment

Exclusion Criteria:

  • pregnancy
  • immunosuppressed
  • former major pelvic surgery or irradiation
  • Rectal prolapse
  • complex fistula
  • IBD
  • Lateral sphincterotomy

Sites / Locations

  • Dep. of Colorectal Surgery, University Hospital of North Norway

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm Type

Active Comparator

Active Comparator

Active Comparator

Arm Label

sacral nerve modulation

anal bulking agents

Anal bulking agents

Arm Description

Implantation of Interstim II-3058 impulse generator after positive PNE test. Randomized controlled trial.

anal injection with Permacol after positive PNE test. Randomized controlled trial.

Anal injection with Permacol after negative PNE test. cohort study.

Outcomes

Primary Outcome Measures

change in St Marks incontinence score
Vaizey Incontinence Score A scale from 0-24 where 0 = perfect continence and 24 = complete incontinence. 3, 6 and 12 months

Secondary Outcome Measures

change in number of fecal incontinence and urgency episodes per week
change in Quality of life assessment (Rockwood- Fecal incontinence quality of life )
change in FIQL and EQ-5D
change in urinary incontinence score (ICIQ-UI SF)
International consultation on incontinence modular questionnaire, ICIQ-UI Short form, A scale from 0-21 where 0 = perfect continence and 20 = complete incontinence.
change in sexual function

Full Information

First Posted
January 26, 2012
Last Updated
June 20, 2016
Sponsor
University Hospital of North Norway
search

1. Study Identification

Unique Protocol Identification Number
NCT01528995
Brief Title
Treatment of Fecal Incontinence After Obstetric Anal Sphincter Injuries
Acronym
KISS
Official Title
A Blinded Randomized Controlled Clinical Trial Comparing Sacral Nerve Modulation and Anal Bulking Injections as Treatment for Fecal Incontinence After Obstetric Anal Sphincter Injuries (OASIS).
Study Type
Interventional

2. Study Status

Record Verification Date
June 2016
Overall Recruitment Status
Completed
Study Start Date
February 2012 (undefined)
Primary Completion Date
September 2015 (Actual)
Study Completion Date
September 2015 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University Hospital of North Norway

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Fecal incontinence (FI), the involuntary loss of solid or liquid stool, is a stigmatising condition. It can have a distressing impact and restriction on quality of life. Obstetric-related fecal incontinence may occur early after childbirth. Previous obstetric injury is a major cause of fecal incontinence in older women. When conservative treatment fails, surgery may be an option. Both sacral nerve modulation and anal bulking injections is minimal invasive surgical alternatives. Step one in SNM is a trial period of temporary stimulation. If the test is successful, the patient can have an implantable stimulator (step 2). Transanal submucosal bulking injection of collagen is also a possible treatment option and can be an effective treatment for faecal incontinence. The purpose of this study is to compare the efficacy of sacral nerve stimulation to anal bulking injections in women with fecal incontinence after obstetric sphincter injuries (OASIS), through a multicenter blinded, randomized controlled trial.
Detailed Description
Obstetric anal sphincter injuries (OASIS) is the most common cause of fecal incontinence (FI) in women. Obstetric-related FI may occur early after childbirth. Previous obstetric injury is also a major cause of FI in older women, and risk of FI increases with time and further childbirths. FI is involuntary loss of solid or liquid stool. Symptoms range from fecal urgency, soiling, to daily passive or urge fecal incontinence. FI is a stigmatizing condition. It can have a distressing impact and restriction on quality of life, including isolation and depression. Tears during delivery is classified (Sultan) as first degree tears including vaginal epithelium, second degree tears into the perineal muscle, third degree involving the anal sphincter complex and fourth degree including sphincter complex and anorectal epithelium. OASIS includes third and fourth degrees tears. First line of therapy of FI is conservative treatment including drug therapy and "biofeedback". If conservative treatment fails, surgery may be an option. Traditionally elective secondary sphincter repair has been performed at least once. Sphincter repair may improve symptoms in short time, but efficacy deteriorates with time. Other minimal invasive surgical alternatives includes sacral nerve modulation (SNM) and anal bulking injection. Sacral nerve modulation involves stimulating the sacral nerves, usually S3 or S4. Step one is a trial period of temporary stimulation (PNE test). If the test is successful, the patient can have an implantable stimulator (step 2) to modulate sacral nerve function. SNM is also beneficial for treating FI after OASIS, and SNM is a alternative to secondary sphincter repair. SNM should possibly be preferred second line treatment also after sphincter tears related FI. Transanal submucosal bulking injection of collagen is also a possible treatment option and can be an effective treatment for both anal and fecal incontinence. The purpose of this study is to compare the efficacy of sacral nerve modulation to anal bulking injections in women with fecal incontinence after OASIS through a Scandinavian multicenter single-blinded, randomized controlled trial. To answer the research question, we will include 66-86 women with FI after OASIS. Sphincter defects are classified using three dimensional endoanal ultrasonography. Pelvic floor function including FI is registered using validated questionnaires. All women eligible for inclusion is PNE-tested for three weeks. The purpose of this cohort analysis, is to examine the possible effect of SNM in women with sphincter defects, and the hypothesis is that there is no relation between sphincter defect classified using tree dimensional ultrasound and efficacy of SNM. Women with more than 50 % symptom reduction during PNE test (positive PNE test), is further randomized and allocated 1:1 into one of two arms with 28 participants. One group is allocated to implantation of permanent impulse generator, Interstim II-3058 and the other group is allocated to anal sub mucosal bulking injection of collagen, Permacol. The purpose of this study is to compare the efficacy of SNM to anal bulking injection. The hypothesis is that SNM provides a mean change in improvement in St Marks Incontinence score of more than 4 compared to the anal bulking group. This study is designed as a multicenter single-blinded, randomized controlled trial. Women with less than 50 % symptom reduction (15-28, negative PNE test), is treated in a third arm with anal bulking injection. The purpose of this cohort study, is to examine the efficacy of anal bulking injection in women suffering from FI after sphincter tears, excluded from further treatment with SNM.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Fecal Incontinence
Keywords
fecal incontinence, anal incontinence, obstetric sphincter injuries, OASIS, double incontinence, urinary incontinence, sexual function, sacral nerve modulation, sacral nerve stimulation, Interstim, anal bulking injections, Permacol

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
Outcomes Assessor
Allocation
Randomized
Enrollment
68 (Actual)

8. Arms, Groups, and Interventions

Arm Title
sacral nerve modulation
Arm Type
Active Comparator
Arm Description
Implantation of Interstim II-3058 impulse generator after positive PNE test. Randomized controlled trial.
Arm Title
anal bulking agents
Arm Type
Active Comparator
Arm Description
anal injection with Permacol after positive PNE test. Randomized controlled trial.
Arm Title
Anal bulking agents
Arm Type
Active Comparator
Arm Description
Anal injection with Permacol after negative PNE test. cohort study.
Intervention Type
Device
Intervention Name(s)
Medtronic Interstim II-3058
Intervention Description
impulse generator
Intervention Type
Procedure
Intervention Name(s)
Anal bulking injection
Intervention Description
Permacol injection: four submucosal injections are administered at the 12, 3, 6 and 9 o'clock positions, above the level of the dentate line. The injection produces a bulge in the mucosa
Primary Outcome Measure Information:
Title
change in St Marks incontinence score
Description
Vaizey Incontinence Score A scale from 0-24 where 0 = perfect continence and 24 = complete incontinence. 3, 6 and 12 months
Time Frame
6 month after treatment
Secondary Outcome Measure Information:
Title
change in number of fecal incontinence and urgency episodes per week
Time Frame
3 and 6 month after treatment
Title
change in Quality of life assessment (Rockwood- Fecal incontinence quality of life )
Description
change in FIQL and EQ-5D
Time Frame
3 and 6 month
Title
change in urinary incontinence score (ICIQ-UI SF)
Description
International consultation on incontinence modular questionnaire, ICIQ-UI Short form, A scale from 0-21 where 0 = perfect continence and 20 = complete incontinence.
Time Frame
3 and 6 month
Title
change in sexual function
Time Frame
3 and 6 months

10. Eligibility

Sex
Female
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: fecal incontinence after OASIS St Marks score > 8 failure of conservative treatment Exclusion Criteria: pregnancy immunosuppressed former major pelvic surgery or irradiation Rectal prolapse complex fistula IBD Lateral sphincterotomy
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Stig Norderval, PHD MD
Organizational Affiliation
University Hospital of North Norway
Official's Role
Principal Investigator
Facility Information:
Facility Name
Dep. of Colorectal Surgery, University Hospital of North Norway
City
Tromsoe
State/Province
Troms
ZIP/Postal Code
9037
Country
Norway

12. IPD Sharing Statement

Learn more about this trial

Treatment of Fecal Incontinence After Obstetric Anal Sphincter Injuries

We'll reach out to this number within 24 hrs